Market Cap: $8.46B
AI
Arrowhead Pharmaceuticals, Inc.
ARWR
NASDAQ (NASDAQ Global Select)USD
Market Cap: $8.46B
Arrowhead Pharmaceuticals (Ticker: ARWR) is making significant strides in the development of treatments for serious metabolic and genetic diseases. During recent discussions, Chief Medical Officer Jam…
Arrowhead Pharmaceuticals (Ticker: ARWR) recently emphasizes its commitment to advancing siRNA therapeutics, highlighted by key developments shared during a recent Jefferies fireside chat. Chief Medic…
Arrowhead Pharmaceuticals (Ticker: ARWR) announces an exclusive licensing agreement with Madrigal Pharmaceuticals for the development of a therapeutic targeting metabolic dysfunction-associated steato…
Arrowhead Pharmaceuticals (Ticker: ARWR) is at a pivotal moment as it transitions into a commercial phase while focusing on expanding its RNA interference pipeline. At the recent BofA Annual Healthcar…
Arrowhead Pharmaceuticals (ARWR) experiences a significant breakthrough as the Australian Therapeutic Goods Administration grants approval for its innovative drug, REDEMPLO (plozasiran). This latest d…
Arrowhead Pharmaceuticals Advances Gene Editing Innovations Arrowhead Pharmaceuticals is at the forefront of revolutionizing medical treatment through its innovative approaches in RNA-targeted therape…
Arrowhead Pharmaceuticals Makes Strides in Obesity Treatment with Promising Clinical Trial Results Arrowhead Pharmaceuticals is making significant advancements in the field of obesity treatment, as in…
Arrowhead Pharmaceuticals Navigates Market Challenges Amid Broader Economic Concerns Arrowhead Pharmaceuticals faces a complex economic landscape as market downturns continue to shape investor sentime…
Arrowhead Pharmaceuticals: A Surge in Performance Reflecting Strong Strategic Execution Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reveals a significant uptick in its stock value following the rel…
Advancements in Genetic Medicine: A New Chapter for Rare Disease Therapies The recent FDA approval for dosing in Cohort 8 of the ENDEAVOR study conducted by Sarepta Therapeutics Inc. significantly hig…
Arrowhead Pharmaceuticals Advances in Genetic Medicine Landscape Arrowhead Pharmaceuticals, Inc. is making significant strides in the field of genetic medicine, positioning itself as a key player in t…
Arrowhead Pharmaceuticals Focuses on Advancing RNAi-Based Therapeutics Amid Upcoming Earnings Announcement As Arrowhead Pharmaceuticals prepares to announce its quarterly earnings on November 25, 2025…
Arrowhead Pharmaceuticals Advances RNAi-Based Therapeutics Amid Promising Pipeline Developments Arrowhead Pharmaceuticals focuses on the advancement of its innovative RNA interference (RNAi) therapeut…
Arrowhead Pharmaceuticals Secures FDA Approval for Redemplo, a Breakthrough Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. announces a major milestone as the U.S. Food…
Arrowhead Pharmaceuticals Breaks New Ground with Redemplo Approval for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. has achieved a significant milestone with the U.S. Food and Dru…
CRISPR Therapeutics Advances Gene Editing with CTX310 Trial Data In a significant development within the biotechnology sector, CRISPR Therapeutics AG (NASDAQ:CRSP) presents promising Phase 1 data from…
Biotechnology Sector Shows Promising Momentum Recent developments in the biotechnology sector highlight the remarkable advancements in research and innovation that are driving investor confidence and…
Arrowhead Pharmaceuticals: Riding the Wave of Biotechnology Momentum Arrowhead Pharmaceuticals finds itself at a significant juncture within the biotechnology sector, as recent developments highlight…
Arrowhead Pharmaceuticals Navigates Economic Headwinds While Advancing Pipeline Arrowhead Pharmaceuticals, a leader in RNA-targeted therapies, continues to focus on its innovative drug development des…
Arrowhead Pharmaceuticals Navigates the Genetic Therapy Landscape Amidst Industry Developments In the biotechnology sector, advancements in gene therapies are forging new pathways for treatment option…
### Regulatory Setback for Innovative DMD Treatment Arrowhead Pharmaceuticals faces a significant challenge this week as the Committee for Medicinal Products for Human Use (CHMP) of the European Medic…
Arrowhead Pharmaceuticals: Focus on Innovative Therapeutics Amidst Market Optimism Arrowhead Pharmaceuticals continues to carve a niche for itself in the biopharmaceutical industry with its innovative…
Arrowhead Pharmaceuticals: Advancing Targeted Therapies Amid Market Optimism Arrowhead Pharmaceuticals is at the forefront of developing innovative therapies that target specific genetic diseases. The…
Arrowhead Pharmaceuticals Faces Industry Headwinds Amid Biotech Challenges Arrowhead Pharmaceuticals experiences a significant downturn in its stock price, mirroring broader difficulties faced by the…
Arrowhead Pharmaceuticals Faces Challenges Amid Industry Turbulence Arrowhead Pharmaceuticals, a prominent player in the biotechnology sector, experiences a turbulent trading day as it faces significa…